| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
INX-SM-6 targets immune cells, particularly peripheral blood mononuclear cells (PBMCs), where it suppresses the production of the pro-inflammatory cytokine IL-1beta in response to lipopolysaccharide (LPS) stimulation. The specific molecular target has not yet been fully elucidated.
|
|---|---|
| ln Vitro |
In human PBMCs, INX-SM-6 (concentration range not specified in available sources) significantly inhibits LPS-induced IL-1beta production, demonstrating its anti-inflammatory properties. It shows no significant cytotoxicity at effective concentrations based on available data.
|
| ln Vivo |
In vivo activity data are not documented in the available literature, as INX-SM-6 is primarily evaluated in cell-based assays for its anti-inflammatory effects. Further animal studies are needed to validate its efficacy in vivo.
|
| Enzyme Assay |
Detailed protocols for cell-free receptor binding assays are not available. The compound's mechanism is primarily studied in cell-based systems measuring its effects on cytokine production, making traditional cell-free enzymatic assays less applicable at this stage of research.
|
| Cell Assay |
Human PBMCs isolated from healthy donors are seeded in 96-well plates. Cells are pre-incubated with varying concentrations of INX-SM-6 (e.g., 0.1-100 uM) for 1-2 hours, then stimulated with LPS (1 ug/mL) for 18-24 hours. IL-1beta levels in culture supernatants are quantified by ELISA. Cell viability is assessed by MTT or CellTiter-Glo to confirm that inhibition is not due to cytotoxicity.
|
| Animal Protocol |
Detailed in vivo animal protocols are not available. Based on the compound's intended use, potential protocols would involve administration in rodent models of inflammation (e.g., LPS-induced endotoxemia, colitis, or arthritis) via intravenous or intraperitoneal injection, followed by measurement of IL-1beta and other inflammatory markers in blood and tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not documented. As an ADC payload candidate, INX-SM-6 is expected to have favorable stability and solubility properties for conjugation to antibody-drug linkers. Solubility: DMSO ≥ 50 mg/mL (~86.70 mM). For in vitro use, stock solutions are prepared in DMSO. Stable at -20degC as powder and in solvent at -80degC for 6 months.
|
| Toxicity/Toxicokinetics |
Standard safety precautions for research chemicals apply. INX-SM-6 is for laboratory use only. Avoid inhalation, ingestion, and skin contact. Use personal protective equipment and work in a well-ventilated area. Store in a sealed, moisture-protected environment, preferably under nitrogen, at -20degC in powder form.
|
| References | |
| Additional Infomation |
This is a research-grade compound, not an approved drug. It is part of a class of molecules designed for antibody-drug conjugate (ADC) applications, where it serves as a cytotoxic payload for targeted anti-inflammatory therapy. Molecular formula: C32H36N2O6S; molecular weight: 576.70. Purity: ≥98%. Also investigated in oncology.
|
| Molecular Formula |
C32H36N2O6S
|
|---|---|
| Molecular Weight |
576.70
|
| Exact Mass |
576.229
|
| CAS # |
2734878-16-9
|
| PubChem CID |
164517030
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
41
|
| Complexity |
1160
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
O=C1C=C2[C@]([C@]3([H])[C@]([H])([C@@]4([H])[C@@]([C@]5([C@](C4)([H])O[C@@H](C4=CN=C(S4)CC4=CC(N)=CC=C4)O5)C(=O)CO)(C[C@@H]3O)C)CC2)(C)C=C1
|
| InChi Key |
NJJMSRHGOQXBCC-CIIJGLHGSA-N
|
| InChi Code |
InChI=1S/C32H36N2O6S/c1-30-9-8-20(36)12-18(30)6-7-21-22-13-26-32(25(38)16-35,31(22,2)14-23(37)28(21)30)40-29(39-26)24-15-34-27(41-24)11-17-4-3-5-19(33)10-17/h3-5,8-10,12,15,21-23,26,28-29,35,37H,6-7,11,13-14,16,33H2,1-2H3/t21-,22-,23-,26+,28+,29+,30-,31-,32+/m0/s1
|
| Chemical Name |
(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-[2-[(3-aminophenyl)methyl]-1,3-thiazol-5-yl]-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~86.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7340 mL | 8.6700 mL | 17.3400 mL | |
| 5 mM | 0.3468 mL | 1.7340 mL | 3.4680 mL | |
| 10 mM | 0.1734 mL | 0.8670 mL | 1.7340 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
